1	Full Title: Development and validation of a multiplex real-time qPCR assay using GMP-
2	grade reagents for leprosy diagnosis
3	
4	Short running head: Multiplex qPCR for leprosy diagnosis
5	
6	Author names and affiliations.
7	Fernanda Saloum de Neves Manta ¹ ¶, Thiago Jacomasso ² ¶, Rita de Cássia Pontello
8	Rampazzo ² , Suelen Justo Maria Moreira ¹ , Najua Zahra ² , Marcelo Ribeiro-Alves ³ , Marce
9	Aurélio Krieger ^{2,4} , Alexandre Dias Tavares Costa ^{2,4,&*} , Milton Ozório Moraes ^{1&*}
10	¹ Laboratório de Hanseníase, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Rio de
11	Janeiro, Brazil
12	² Instituto de Biologia Molecular do Paraná, Fiocruz, Curitiba, Paraná, Brazil
13	³ Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro, Rio de Janeiro,
14	Brazil
15	⁴ Instituto Carlos Chagas, Fundação Oswaldo Cruz/FIOCRUZ, Curitiba, PR, Brasil.
16	¶ These authors contributed equally to this work
17	^{&} These authors also contributed equally to this work
18	

19 * Corresponding authors:

20 1) Alexandre Dias Tavares Costa (Ph.D).

- 21 Instituto de Biologia Molecular do Paraná / Instituto Carlos Chagas, Fundação Oswaldo
- 22 Cruz/FIOCRUZ, Curitiba, Paraná, Brasil.
- 23 Phone: +55-41-3316-3230; E-mail: alexandre.costa@fiocruz.br
- 25 2) Milton Ozório Moraes (Ph.D).
- 26 Laboratório de Hanseníase, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Rio de
- 27 Janeiro, Brazil

29

31

41

42

- E-mail:milton.moraes@fiocruz.br, Telephone contact: +55-21- 25621556.
- Number of text pages (34); tables (4) and figures (7)
- 32 Grant numbers and sources of support:
- 33 This work was funded by a grants from: Banco Nacional de Desenvolvimento Econômico e
- 34 Social (BNDES), contract no. 15.2.0473.1 (Operation #4.816.864) to MAK, and Novartis
- 35 Foundation and Leprosy Research Initiative (LRI; 703.15.45), Foundation for Research
- 36 Support of the State of Rio de Janeiro (FAPERJ;E-26/203.053/2016), Brazilian National
- 37 Council for Scientific and Technological Development (CNPg; 421852/2017-2018), Brazilian
- 38 Coordination for Improvement of Higher Education Personnel (CAPES), and by the National
- 39 Fund for Health/Brazilian Ministry of Health (MS/SCTIE/DECIT; 404277/2012-8 and TED
- 40 145/2018) to MOM.

Disclosure of conflict of interest

Instituto de Biologia Molecular do Paraná (IBMP) produces the PCR mastermix and some of the oligonucleotides used in the qPCR experiments. In addition, several authors received grants or fellowships from the Brazilian funding agencies CNPq and CAPES. This work was partially funded by grants from BNDES, Novartis Foundation, Leprosy Research Initiative, Foundation for Research Support of the State of Rio de Janeiro (FAPERJ), CNPq, CAPES, and by the National Fund for Health/Brazilian Ministry of Health (MS/SCTIE/DECIT). However, none of the aforementioned institutions had any participation in the present study's design, data collection, analysis, interpretation, or writing of the report and decision to submit for publication.

Abstract

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Leprosy is a chronic dermato-neurological disease caused by Mycobacterium leprae, an obligate intracellular bacterium. Timely detection is a challenge in leprosy diagnosis, relying on clinical examination and trained health professionals. Furthermore, adequate care and transmission control depend on early and reliable pathogen detection. Here, we describe a qPCR test for routine diagnosis of leprosy-suspected patients. The reaction simultaneously amplifies two specific *Mycobacterium leprae* targets (16S rRNA and RLEP), and the human 18S rRNA gene as internal control. The limit of detection was estimated to be 2.29 copies of *M. leprae* genome. Analytical specificity was evaluated using a panel of 20 other skin pathogenic microorganisms and Mycobacteria, showing no cross-reactivity. Intra- and interoperator C_p variation was evaluated using dilution curves of *M. leprae* DNA or a synthetic gene, and no significant difference was observed between three operators in two different laboratories. The multiplex assay was evaluated using 97 patient samples with clinical and histopathological leprosy confirmation, displaying high diagnostic sensitivity (91%) and specificity (100%). Validation tests in an independent panel of 50 samples confirmed sensitivity and specificity of 97% and 98%, respectively. Importantly, assay performance remained stable for at least five months. Our results show that the newly developed multiplex qPCR effectively and specifically detects M. leprae DNA in skin samples, contributing to an efficient diagnosis that expedites the appropriate treatment.

Author Summary

Leprosy is a chronic dermato-neurological disease caused by *Mycobacterium leprae*, an obligate intracellular bacterium. Disease diagnosis is currently performed on skin examinations for clinical signs, bacilli staining in skin smears and invasive skin biopsies. However, the spectrum of clinical manifestations and the low bacterial load can hinder accurate diagnosis, which is critical for providing proper intervention and adequate care as well as for establishing transmission control. Quantitative PCR (qPCR) methods for detecting bacterial DNA are more sensitive and could aid in differentially diagnosing leprosy from other dermatological conditions. In this work, we present a new multiplex qPCR that detects two bacterial genes for the diagnosis and a human gene as an internal reaction control. The new qPCR, developed using GMP-grade reagents, is highly sensitive, specific, reproducible, and stable. The results presented here are the basis of a novel and robust tool with potential to increase the accuracy of leprosy diagnosis in routine or reference laboratories.

Keywords

- leprosy; diagnostic; qPCR; good manufacturing practices; validation; neglected tropical
- 97 diseases; *Mycobacterium leprae*; internal control

Introduction

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Leprosy is a neglected infectious disease that still represents a public health issue (1) with more the 200,000 cases every year worldwide. Diagnosis is generally late and, although a specific and effective treatment is available, it is likely that transmission occurs before the patient is diagnosed and adequately treated, thus contributing to sustained transmission. The high number of young patients (under 15 years old) and patients with disabilities due to advanced stage of the disease, confirms this hypothesis (1). Furthermore, clinical forms vary to a great extent, from localized (tuberculoid) to disseminated (lepromatous) forms, making diagnosis difficult. Evidence suggests that early diagnosis could prevent transmission and help epidemiological control (2). Methods such as bacterial load detection by microscopy and histopathological examination have been the main complementary tools for the diagnosis of leprosy (2-4). Classical bacteriological methods cannot confirm leprosy since M. leprae does not grow in vitro. In addition, there is no reliable marker to estimate the risk of disease progression (5,6). In this regard, the sequencing of *M. leprae* genome (7) was a milestone towards the improvement of direct *M. leprae* detection, leading not only to better characterization of genomic targets unique to *M. leprae* strains but also to an extensive comparison of different mycobacteria. At the time of the first sequences became available, the polymerase chain reaction (PCR) technique was laborious and very expensive, averting its universal application. However, as PCR was further developed, it became more affordable, versatile and reliable, with fully automated systems becoming commercially available from different companies (8–10). For tuberculosis, routine tests using PCR are reducing the turnaround time, allowing same day treatment initialization, which might impact resistance prevalence (11-13). Cost-effective

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

nucleic acid detection assays are relatively widespread, but assays for some neglected diseases are still missing. In leprosy, the situation is even more difficult due to reduced and late investments directed to diagnostic tests (14). In the last few years, many studies have been carried out using the PCR technique to detect M. leprae DNA in clinical specimens. PCR have been used especially under challenging diagnoses such as equivocal paucibacillary (4,15-18) or monitoring household contacts (19,20). In this context, several different targets have been described in an attempt to establish the most sensitive and specific assay (16,20-28). However, most of the PCR protocols were developed, evaluated, and validated using reagents or tests produced without good manufacturing practices (GMP). Also, most of the studies enroll only leprosy patients and do not recruit patients with other common dermatological diseases that are differential diagnosis to leprosy. Thus, the development and validation of an assay over different laboratories has become a necessity. Here, we present the development and validation of a multiplex real-time PCR assay aiming to standardize the leprosy molecular diagnostic assay. The protocol was designed to simultaneously detect two M. leprae targets (16SrRNA and RLEP genes), previously used in several studies (4,16,19,26,29), and one mammalian target (18S rRNA gene), that serves as reaction control (30). Cross-reactivity was evaluated using DNA from 20 related mycobacterial and other skin pathogenic species, and no match was found. The new assay was validated using 97 skin biopsies and an independent panel enrolling 50 samples retrieved from patients previously characterized by clinical examination and histopathology, showed high sensitivity and specificity. The new multiplex PCR was also assessed for quality control standards and the data indicate that the assay is stable and reproducible. The results presented here are the basis of a novel and robust tool with potential to increase the accuracy of leprosy diagnosis in routine or reference laboratories.

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Material and methods Ethics statement The Ethics Committee of the Oswaldo Cruz Foundation approved this study (CAAE: 38053314.2.0000.5248, number: 976.330-10/03/2015). Written informed consent was obtained from all patients 18 years or older, or from the parents/guardian of patients under 18. **Clinical samples** Leprosy patients were enrolled from the Leprosy clinic from the Oswaldo Cruz Foundation in the city of Rio de Janeiro, Brazil. Skin biopsies were collected using a 6-mm punch and stored in 70% ethanol at -20 °C until processing. Ninety-seven samples (53 skin biopsies from leprosy patients and 44 skin biopsies from patients with other skin diseases) were used for qPCR tests. Clinical and demographic

characteristics of all patients are shown in Table 1.

Table 1: Clinical and demographic characteristics of the leprosy and other dermatological

165

166

disease cases

Characteristics	Types	1 st pa	nel	2 nd panel			
		Leprosy group (n=53)	ODD group (n=44)	Leprosy group (n=35)	ODD group (n=15)		
Gender	Male	32	13	25	3		
	Female	21	31	10	12		
Age	1-15	2	2 3		1		
	16-30	8	7	5	2		
	31-45	14	6	11	2		
	46-60	20	19	9	9		
	>60	9	9	7	1		
WHO classification	PB MB	18 35	NA NA	8 27	NA NA		
Clinical form	l	6	NA	0	NA		
	TT	1	NA	3	NA		
	ВТ	11	NA	5	NA		
	BB	5	NA	6	NA		

	BL	3	NA	7	NA
	LL	27	NA	14	NA
Bacterial load	0	23	38	8	15
	0-2	6	0	2	0
	2-4	11	0	13	0
	4-6	13	0	12	0

Other Dermatological Disease (ODD). Operational classifications [paucibacillary (PB) or multibacillary (MB)]. PB individuals were classified as Tuberculoid (TT), Borderline tuberculoid (BT), Indeterminate (I) and Pure Neural (PN). MB individuals were classified as Borderline-borderline (BB), Borderline lepromatous (BL) or Lepromatous (LL). NA: Not Applicable.

Leprosy patients were defined according to the clinical, bacteriological. histopathological Ridley-Jopling (R&J) classification and the operational classification in multibacillary (MB) or paucibacillary (PB) forms according to the WHO (31). Leprosy or other dermatological diseases (ODD) patients were treated according to their respective condition. Leprosy paucibacillary (PB) or multibacillary (MB) patients were treated according to the Ministry of Health recommendations, while ODD patients were treated accordingly for each specific disease.

Replication Study

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

To validate the conditions and analysis parameters established with the clinical samples from Oswaldo Cruz's Leprosy Clinic, we tested a distinct collection of 50 skin biopsy samples that were also obtained by the Leprosy Clinic. The second set of samples was sent to the Global Health Institute, École Polytechnique Fédérale de Lausanne, Switerzland, where DNA samples was extracted and was blindly characterized by conventional PCR according to a previously published protocol (32). The extracted DNA was then sent back to the Leprosy Clinic at Oswaldo Cruz Foundation, where it was blindly analyzed with the qPCR developed in the present study. After both PCR analyses were performed, blinding was removed and the results were compared. Of these 50 samples, fifteen samples were from patients with other skin diseases, 27 patients MB leprosy and eight from PB leprosy. The group presented a 1.27:1 ratio of males to females. The mean age was 44.8 (+/- 17.72 SD), and the range was 8-77. Details on the clinical characteristics are shown in supplementary table 1.

Mycobacterial isolates samples

M. leprae Thai-53 purified from athymic BALB/c (nu/nu) mouse footpads was kindly provided by Dr. Patricia Rosa at the Lauro de Souza Lima Institute, Bauru, São Paulo, Brazil. Purified DNA from M. leprae was used as positive control and in analytical sensitivity studies. DNA from 21 mycobacterial samples were used for the analytical specificity study. L. amazonensis and L. braziliensis was kindly provided by Dr Elisa Cupolillo by the Laboratório de Pesquisa em Leishmaniose (IOC- Fiocruz) and M. avium, M. gordonae, M. manteni, M. africanum subtype I, M. africanum subtype II, M. bovis, M. bovis (BCG), M. canettii, M. fortuitum, M. gordonae, M. intracellulare, M. kansasii, M. microti, M. pinnipedii, M. simiae, and M. tuberculosis were kindly provided by Dr. Phillip Suffys at Laboratório de Biologia Molecular Aplicada a Micobactérias (IOC-Fiocruz).

Synthetic DNA

The synthetic DNA (gBlock®) was purchased from Integrated DNA Technologies (IDT) and consists of a double-stranded DNA containing the sequences of the three genomic targets (RLEP, 16S, and 18S) (S1 Appendix). The lyophilized DNA was reconstituted to 10 ng/μL (corresponding to 1.83 x 10⁹ copies per reaction) in TE pH 8.0, following the supplier's protocol.

DNA extraction

DNA extraction from the biopsies was carried out using DNeasy Blood and Tissue® extraction kit (Qiagen, Germany). The total extracted DNA was quantified with NanoDrop® (Thermo-Fisher Scientific, Waltham, MA, USA) and stored at -20 °C. *M. leprae* DNA from nude mice footpad was purified using TRIzol reagent (Life Technologies, Carlsbad, California) following the manufacturers' instructions, as previously described (3). DNA used in the replication study were extracted using QIAmp UCP Pathogen Mini kit (Qiagen GmbH, Hilden, Germany).

Standard curve and 95% limit of detection (LoD_{95%}) assessment

The standard curve was used for determination of the limit of detection and assay stability. A series of 10-fold dilutions was prepared from either M. Ieprae or synthetic DNA, using DNA purified from human blood obtained from healthy donors as matrix. The dilution series used for the standard curve and the $LoD_{95\%}$ determination spans concentrations from 500 ag/reaction to 5 ng/reaction of purified M. Ieprae DNA, and 1.83 to 1.83 x 10^7 copies/reaction (equivalent to 0.5 ag/reaction and 5 pg/reaction, respectively) of synthetic DNA.

Quantitative PCR (real-time PCR assays)

A multiplex real-time qPCR assay targeting simultaneously two *M. leprae* regions and an internal reference human sequence was developed. The primers and hydrolysis probes were designed to detect regions from RLEP and 16S rRNA genes (29) from *M. leprae*, and the human 18S rRNA (30) (Table 2). Reactions were performed on an ABI7500 Standard instrument (Thermo-Fisher Scientific, Waltham, MA, USA), using Multiplex PCR Mastermix (IBMP/Fiocruz PR, Curitiba, Brazil). For each reaction, 5 µL of DNA solution was added for a 25 µL final volume. Reaction mixtures were prepared in triplicates and amplified at 95 °C for 10 min, and 45 cycles of 95 °C for 15 sec and 60 °C for 1 min. All reactions included a positive control (mouse foot-pad *M. leprae* DNA and/or high-bacterial load lepromatous leprosy patient purified DNA), and water as a non-template control (NTC; PCR reaction without any template DNA).

Table 2: Sequences, concentration, and fluorophores of the oligonucleotides contained in the multiplex qPCR assay.

Target	Sequences	Final concentration	Fluorophore
16SrRNA	Forward: 5'-GCATGTCTTGTGGTGGAAAGC- 3'	0.5 μΜ	FAM
	Reverse: 5'-CACCCCACCAACAAGCTGAT- 3'	0.5 μΜ	
	Probe: 5'-CATCCTGCACCGCA-3'	0.2 μΜ	
RLEP	Forward: 5'-GCAGCAGTATCGTGTTAGTGAA-3'	0.2 μΜ	VIC
	Reverse: 5'-CGCTAGAAGGTTGCCGTAT-3'	0.2 μΜ	
	Probe: 5'CGCCGACGGCCGGATCATCGA-3'	0.1 μΜ	
18s RNA	Forward: 5'-	0.06 μM	CY5
	GAAACTGCGAATGGCTCATTAAATCA- 3'	0.06 µM	

Reverse: 5'-CCCGTCGGCATGTATTAGCTCT-3'	0.03 μΜ	
Probe: 5'GGAGCGAGCGACCAAAGGAACCA-3'		

Stability

246

247

248

249

255

256

257

258

259

260

261


- The stability of the new multiplex qPCR was evaluated the synthetic DNA template diluted
- in TE to the concentrations of approximately 2×10^8 , 2×10^7 , 2×10^6 , 2×10^6 , 2×10^5 , 2×10^6
- 251 10^4 , 2 x 10^3 , 2 x 10^2 , 2 x 10^1 , 10, 5, and 2.5 copies per reaction.
- 252 All reagents (oligomix 25X and qPCR mix) were maintained in independent aliquots at -20
- 253 °C at the Leprosy Laboratory (Fiocruz-RJ). Tests with the dilution series described above
- were repeated weekly for the first month, and then once a month for five months.

Data Analyses and Statistics

Qualitative (diagnostic sensitivity and specificity, accuracy) and quantitative (intra- and interlaboratory repeatability and reproducibility, analytical sensitivity and specificity) validation tests were performed. The 95% limit of detection (LoD_{95%}) was calculated by fitting a Probit model to the estimated detection probabilities. Data were processed and analyzed using customized scripts for R version 3.5.1 (downloaded from http://www.Rproject.org/).

Results

Analytical performance



279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

Fig 1. Standard curves of the amplification of 16SrRNA and RLEP targets in M. leprae DNA and in a synthetic construct. Panels A and C show the calibration curves obtained using *M. leprae* DNA, diluted in total DNA extracted from *M. leprae*-negative whole blood. Continuous lines show the linear range and the dashed lines are extrapolations towards the non-linear range. Efficiencies calculated from the linear ranges were 99.2% for 16SrRNA and 102.2% for RLEP, and r² were 0.9968 and 0.9987, respectively. Panels B and D show the calibration curves obtained using a synthetic gene containing one copy of each target per molecule, diluted in total DNA extracted from M. leprae-negative whole blood. The efficiencies were 94.9% for 16SrRNA and 93% for RLEP, and r² were 0.9874 and 0.9926, respectively. The analytical 95% limit of detection (LoD_{95%}) was determined from a series of tests in which DNA extracted from M. leprae was diluted from 5 ng to 100 ag/reaction. Figure 2 shows the fitted Probit models and the obtained LoD_{95%} for 16S rRNA and RLEP, which were experimentally determined as approximately 450 fg of DNA (ca. 126 M. leprae genomes) for the 16SrRNA gene and about 4.60 fg of DNA (ca. 1.3 M. leprae genomes) for the RLEP gene.




Fig 2. Analytical 95% limit of detection (LoD_{95%}) for 16SrRNA and RLEP in multiplexed **qPCR**. *Mycobacterium leprae* DNA was diluted in DNA extracted from whole blood from healthy donors and tested from 5 ng to 0.5 fg/reaction. Probability of detection was calculated for 16S and RLEP (tom and bottom panels, respectively) from nine independent experiments, and a Probit model was fit to the data (black lines). The grey ribbon around the model fit indicates the 95% CI on the predicted probability. Dotted lines indicate the

interpolation to determine the concentration at a 95% probability. The calculated $LoD_{95\%}$ is displayed on each plot in femtograms of DNA/reaction.

The developed multiplex reaction was evaluated against a collection of microorganisms to assess the specificity of the primers and probes under these conditions. The selection included several mycobacteria, as well as a few other pathogens associated with skin diseases such *Leishmania* (figure 3). We only considered any species as cross-reactive if all the technical replicates displayed amplification for at least one of the targets which was not the case for any of the species tested. Most positive amplifications observed correspond to RLEP, which was detected in two out of three replicates in *M. fortuitum* and *M. kyroniense*. Even though some reactions presented 16S rRNA signals above the threshold, these amplifications are very uncharacteristic and are easily distinguishable from a proper amplification when compared with the positive control with 500 fg/reaction of *M. leprae*.




Fig 3. Analytical specificity for the 16SrRNA and RLEP multiplexed reactions.

Extracted DNA from the indicated microorganisms (5 ng/µL each) were used in the

multiplexed reactions performed in technical triplicates in two independent experiments. Results are compared to the amplification plot for 100 fg *M. leprae* DNA/µL (top-left panel). Amplification profiles are shown for each target, and each line corresponds to one individual well. The dotted lines indicate the threshold for RLEP (which is the highest of the two *M. leprae* targets, at 0.2).

Repeatability and reproducibility

Three independent operators performed three replicate runs each, in consecutive days, and evaluated the repeatability and reproducibility of the multiplex reactions. For each replicate, a new dilution series for the synthetic gene was prepared from a concentrated aliquot to be used as template. Table 3 shows the relative deviations observed within and between operators, respectively. The data shows that all intra-operator replicates were remarkably reproducible, with only one point (Op. 1, 16S, 1.83 x 10²) displaying a relative standard deviation (rRSD%) above 5%, but still well below 10%. The inter-operator variability was also very low, and the largest variation was observed for the 16S target. Nonetheless, the rRSD% was between 1.38 and 11.57 across the dilution range, which shows an excellent reproducibility for a quantitative test (see also supplementary table 2).

Table 3. Precision measurement for repeatibility and reproductibility.

Dranisian							F	recisio	n				
Precision Intra-operator (repeatibility)								Inter-operator					
	Synthetic gene							(reproductibility)					
copies/reaction		Oį	perato	ator 1 Operator 2 Operator 3		r 3							
		C _p mean	SD	rRSD%	C _p mean	SD	rRSD%	C _p mean	SD	rRSD%	C _p mean	SD	rRSD%
	1.83E+00	37.41	0.60	1.61	37.15	0.24	0.65	38.14	0.36	0.95	37.57	0.52	1.38
	1.83E+01	33.83	0.08	0.25	34.84	0.16	0.45	35.67	0.08	0.23	34.78	0.92	2.65
	1.83E+02	32.85	2.58	7.84	31.65	0.11	0.35	32.79	0.27	0.82	32.43	0.68	2.09
16S	1.83E+03	27.96	0.03	0.10	27.97	0.06	0.21	29.66	0.08	0.28	28.53	0.98	3.43
105	1.83E+04	24.21	0.16	0.65	24.36	0.10	0.42	26.17	0.04	0.15	24.91	1.09	4.38
	1.83E+05	20.60	0.59	2.88	20.99	0.06	0.31	21.66	0.83	3.83	21.08	0.53	2.53
	1.83E+06	16.96	0.19	1.14	17.09	0.79	4.63	17.97	0.32	1.79	17.34	0.55	3.15
	1.83E+07	12.27	0.31	2.49	11.95	0.10	0.86	14.69	0.15	1.01	12.97	1.50	11.57
-	1.83E+00	36.21	0.55	1.51	37.76	0.71	1.89	37.34	0.14	0.37	37.10	0.80	2.16
	1.83E+01	34.90	1.09	3.13	36.18	0.09	0.25	34.84	0.15	0.43	35.30	0.75	2.14
	1.83E+02	33.92	0.55	1.62	32.73	0.05	0.16	31.57	0.29	0.92	32.74	1.17	3.58
RLEP	1.83E+03	30.22	0.02	0.06	29.20	0.07	0.23	28.25	0.05	0.19	29.22	0.99	3.37
IVELI	1.83E+04	26.40	0.23	0.87	25.60	0.06	0.23	24.87	0.04	0.17	25.62	0.76	2.98
	1.83E+05	22.36	0.61	2.75	22.05	0.01	0.05	20.35	0.90	4.42	21.59	1.08	5.01
	1.83E+06	18.48	0.24	1.31	18.10	0.86	4.74	16.82	0.35	2.06	17.80	0.87	4.87
	1.83E+07	13.86	0.29	2.06	13.03	0.11	0.86	13.49	0.12	0.90	13.46	0.41	3.08

The accuracy of the determinations performed by the multiplex real-time qPCR assay was also estimated using the synthetic DNA. To evaluate the intra- and inter-repeatability (or intermediate precision) for operators, we calculated the arithmetic mean, standard deviation,

and relative standard deviation percentage of three independent experiments. It is noteworthy that the detection of the human target 18S rRNA does follow the same dilution trend for the other targets because the synthetic template was not diluted in human DNA. In summary, for both *M. leprae* targets we observed that all points showed excellent reproducibility and repeatability. As expected, detection of the human target 18SrRNA loses reproducibility as it becomes scarce in the reaction due to the dilution factor. It is noteworthy that there is no variation in the detection of the human target 18S rRNA when *M. leprae* DNA was present in the synthetic control molecule, i.e., in a 1:1 ratio, supporting the notion that the multiplexed reactions do not interfere with each other (data not shown).

Stability

Storage stability was assessed by performing monthly evaluations of reactions with different concentrations of the synthetic DNA molecule for 5 months. Most of the data points tested varied below the established limit of three standard deviations above the average of all time points. Figure 4 shows the C_p obtained for the three evaluated targets (16SrRNA, RLEP, and 18SrRNA) in representative concentrations for brevity, over a 5-month period. The test remained reliable for the entire range of concentrations tested.




Fig 4. Stability of the reactions over five months using synthetic DNA as a template.

Each panel shows the C_p values obtained for each target (lines of panels) and for each template concentration (columns of panels) over time. Points represent one technical replicate. Black horizontal lines indicate the upper tolerance limit defined as three standard deviations above the mean C_p for each template concentration.

Diagnostic performance




Fig 5. Diagnostic performance of the new multiplex qPCR. Different combinations of cutoff values for 16SrRNA (panels) and RLEP (color scale) were tested on a patient panel (n = 97). For each combination of cutoff values, the sensitivity and specificity were calculated and plotted as ROC curves. Here, only C_p cutoff values for 16SrRNA between 35 and 36.5 are shown. The combinations resulting in a specificity of 1 and the highest sensitivity for each condition are annotated.

Based on these results, the best combination of cutoff values (35.5 for 16SrRNA and 34.5 for RLEP) showed a sensitivity of 91% and specificity of 100%. These parameters were used to establish the decision algorithm presented in Table 4.

Table 4. Decision algorithm for classification of samples based on the data obtained with the new multiplex qPCR.

Results	Classification
18SrRNA negative	Extraction failure (repeat extraction)
18SrRNA C _p between 13 and 32	Valid reaction (proceed with classification)
RLEP < 34.5 and 16S < 35.5	M. leprae detected
RLEP < 34.5 and 16S ≥ 35.5	Equivocal (mark patient for new sample
	collection and testing)
RLEP ≥ 34.5	M. leprae undetected

Next, the molecular diagnosis obtained using the new multiplex PCR, was compared to the clinical diagnosis of each sample (Figure 6 and supplementary table 4). Results show that the qPCR reaction and classification algorithm correctly characterized 48 of the 53 samples previously described as "Leprosy" by the clinical outcome. Of the 5 misclassified samples, one was classified as negative for *M. leprae* and four were in the "equivocal" quadrant. The Bacterial load for the 5 misclassified samples were 0.




Fig 6. Distribution of C_p values obtained for the training panel. Each point represents a different sample (mean C_p s of a technical duplicate). Filled circles represent leprosy samples and open dots represent negative samples, as defined by the clinical assessment. Points aligned to the top and right margins indicate samples in which 16SrRNA or RLEP, respectively, were not detected within 45 cycles. Bacterial load is show as a color gradient (samples for which bacterial load information was not available are filled in grey). Dotted red lines indicate the cutoff values from Table 3. Equivocal or misclassified samples are annotated with the operational classification (false negatives) or with the diagnosis for clinic-negative samples.

None of the 44 samples characterized as "Other skin diseases" were classified as *M. leprae*-positive by our reaction and decision algorithm. Thirty-eight of these samples were classified as "Negative" and 6 as "equivocal".

Assay validation

Conditions established with the training cohort were tested on an independent set of samples, which were previously characterized using a distinct qPCR method described in Girma et al. (32). The comparison between the original classification and the new results is shown in figure 7 and supplementary table 1. We tested 50 samples, of which 34 were previously characterized as positive and 16 as negative.




Fig 7. Validation of parameters on a in an independent panel. Previously characterized validation samples were subjected to the new qPCR described in the present study. Each point represents a different sample. Filled circles represent leprosy samples and open dots represent negative samples, as defined by Girma *et al.* Points aligned to the top and right margins indicate samples in which 16SrRNA or RLEP, respectively, were not detected within 45 cycles. Bacterial load is show as a color gradient (samples for which bacterial load information was not available are filled in grey). Dotted red lines indicate the cutoff values from Table 3.

The 50 samples were classified according to our algorithm, resulting in 33 correctly classified as positive and 11 correctly classified as negative. Of the four samples classified as equivocal, two were negative for the reference method and one was positive according to Girma et al (32). The sensitivity, specificity and accuracy calculated for this sample set were 97.1%, 100% and 98%, respectively.

Discussion

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

Leprosy is a chronic infectious disease presenting great diversity of clinical forms with distinct immunological and histopathological features. Leprosy can be tuberculoid, which is a localized form exhibiting few or no bacteria, or lepromatous, which is a systemic form with high loads of mycobacteria. Among the tuberculoid patients, there is a range of skin granulomatous diseases phenotypically comparable to leprosy (5). The use of PCR for leprosy diagnosis has been extensively tested (4,16,33–44). However, limitations towards the experimental designs for some published studies were identified. We observed that most studies: (i) test only samples from leprosy patients, creating difficulties in determining some diagnostic parameters such as specificity; (ii) were performed on small sample sizes; and (iii) do not have independent validation on the same assay or an evaluation of the same protocol in different centers. Furthermore, no studies have used reagents produced under good manufacturing practices (GMP), a set of guidelines that allow for traceability and batch-to-batch reproducibility of characteristics such as physical parameters and performance of the reagents (45). In this study, we solved some of these issues by (i) developing and validating an assay based on the two most tested targets in the literature with better accuracy so far (7.8,41,46). (ii) following guidelines for validation of diagnostic tests (45,47,48), and (iii) using GMP grade reagents. We were also able to include a reaction for the detection of human 18S gene in the sample, to assess the quality of DNA extraction and reagents performance in the same reaction as the *M. leprae* determination occurs. RLEP and 16SrRNA are the most frequent markers used in leprosy studies, displaying PCR sensitivity values up to 80% for each target. However, it is important to note that the

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

sensitivity of targets varied between sample types, clinical settings, and also between studies of the same authors (8,9). Tatipally et al. (9) showed that using more than one marker in a multiplex format of conventional endpoint PCR yields significantly higher PCR positivity. In the currently study, a multiplex qPCR assay simultaneously amplifies two specific Mycobacterium leprae targets (16SrRNA and RLEP), and the mammalian 18SrRNA gene as internal reaction control. The assay validation comprised analytical performance, diagnostic sensitivity and specificity, as well as reproducibility and repeatability. Development of multiplex qPCR assays provides a greater challenge than designing singleplex assays because it often requires extensive optimization as primer-dimers and non-specific interactions may interfere with amplification of the desired targets. Additionally, it is important that the amplification of two or more targets does not preferentially amplify one of the targets (49,50). Combining multiple primers and probes did not affect the efficiency of the triplex qPCR in comparison to the corresponding singleplex reactions used in Martinez et al. (16), who evaluated the independent detection of 16S and RLEP using the same primers and probes and obtained 0.91 and 0.51 for sensitivity and 0.73 and 1 for specificity, respectively. Barbieri et al. (4) also used the same 16S target to evaluate paucibacillary leprosy samples and obtained 0.57 for sensitivity and 0.91 for specificity. Here, we evaluated a panel with 53 leprosy and 44 non-leprosy patient samples, and later a different sample panel (50 patient samples) and achieved high sensitivity (> 90%) and specificity (100%) for both panels tested. However, we understand that the small number of paucibacillary (PB) individuals in our study is a limitation. In fact, the greatest importance of using qPCR as a complementary diagnosis is precisely for PB samples. Generally, PB patients exhibit low (or zero) bacterial load and a histopathology examination that does not distinguish from the diagnosis of other

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

dermatoses. Therefore, these are the cases where clinical evaluation alone might not be able to determine the diagnosis, and where a gPCR confirmation becomes more important. However, due to the scarcity of bacterial DNA in these sample, it is known that the detection of *M. leprae* in PB patients by real-time PCR is difficult (4). The reactions we developed in this study predict the equivocal classification of early-stage infections based on the finding from Martinez et al. (16), who showed that RLEP displays higher sensitivity than 16S whereas the ribosomal gene displays higher specificity. Thus, samples lacking 16S amplification but with RLEP amplification with a C_p lower than the threshold are suggested to be re-analyzed. In general, our data (figure 6) show a correlation between BI and C_p values. Biopsies from patients with higher BI values were deemed positive for bacteria earlier in the amplification cycle, as seen by the lower Cp values and high copy numbers of bacilli. The "analytical sensitivity" or "limit of detection" of an assay is defined as the ability of the assay to detect very low concentrations of a given substance in a biological specimen (45). The result of the limit of detection (LoD_{95%}) determination when tested on a purified *M. leprae* sample indicated a higher sensitivity for RLEP (4.6 fg of DNA/reaction, equivalent to approximately 1.3 *M. leprae* genomes) versus 16S (450 fg of DNA/reaction, approximately 126 M. leprae genomes). This difference in sensitivity was expected since the 16SrRNA is a single copy gene (29) and the RLEP presents an average of 36 copies per genome (26). Applicability in a reference laboratory setting was also considered during the development of these reactions. Intra and inter-operator variability were low, ensuring consistent results in routine testing (table 3). Moreover, reagents remained stable for at least five months, allowing for adequate stock maintenance (figure 4).

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

Leprosy is a silent disease with a very long incubation time. Currently, transmission can only be halted if patients obtain early diagnosis. High-risk individuals, which are the patients' close contacts, should be traced and treated whenever leprosy is detected. Recently, it has been suggested that novel policies towards this group of contacts such as immuno- and chemoprophylaxis are effective to help control the disease burden (15,51,52). These approaches provide a screening of the high-risk population that, coupled with a pharmacological or immunological intervention, has been suggested to decrease disease incidence. In some situations, clinical diagnosis needs the accuracy support of a laboratory analysis, and gPCR is a reliable technique to enable diagnostic confirmation (10). Indeed, we confirmed that the availability of molecular tests can be very helpful in diagnosing patients during contact monitoring (53). When contacts present a leprosy-like lesion, a positive PCR resulted in a leprosy diagnosis with 50% sensitivity and 94% specificity (53). Other indirect methods based on simultaneous detection of host humoral as well as cellular immune response directed against the bacteria are also promising new diagnostic tools. Recently, lateral flow assays (LFA), combining detection of mycobacterial components and host proteins, proved to be specific and sensitive (54–60). The signature detected by this platform identified 86% of the leprosy patients, with a specificity of 90% (AUC: 0.93, p < 0.0001) (58). Thus, a multicentric study comparing different available methods such as qPCR and LFA is still necessary. It is noteworthy that our data showed accuracy, sensitivity, and specificity values quite similar to LFA. We believe that the diagnosis of tropical and neglected diseases needs molecular-based methods such as PCR, especially due to the robustness and capillarity of the technique in clinical analysis laboratories worldwide. Towards that future, we present a real-time quantitative PCR produced with GMP reagents that adheres to all quality control

specifications, allowing batch-to-batch performance reproducibility and repeatability, and that can be used in research and clinical laboratories with reasonable infrastructure in endemic countries. Finally, we envision the multiplex qPCR assay developed adapted to more affordable, rapid, point-of-care tests to be used in low-resourced settings, enabling on-site early and specific diagnosis of leprosy, hopefully helping disease control.

Acknowledgments

The authors are grateful to the entire team of dermatologists, nurses, and technicians that collaborate at the Souza Araújo Clinic from the Leprosy Laboratory at the Oswaldo Cruz Institute. The authors are also grateful for the excellent technical assistance by Aline Burda Farias, Nilson José Fidêncio and Sylvia Mara Bohn at IBMP. We thank the Laboratório de Pesquisa em Leishmaniose (IOC- Fiocruz) and Laboratório de Biologia Molecular Aplicada a Micobactérias (IOC-Fiocruz) for donating the DNA from mycobacterial samples used in the analytical specificity study.

References

550

551

- 552 1. WHO | A guide for surveillance of antimicrobial resistance in leprosy: 2017 update.
- 553 https://www.who.int/lep/resources/9789290226192/en/
- 554 2. Sarno EN, Duppre NC, Sales AM, Hacker MA, Nery JA, Matos HJ de. Leprosy
- exposure, infection and disease: a 25-year surveillance study of leprosy patient
- contacts. Mem Inst Oswaldo Cruz. 2012 Dec;107(8):1054–9.
- 557 3. Shepard CC, McRae DH. A method for counting acid-fast bacteria. Int J Lepr Other
- 558 Mycobact Dis; 36(1):78–82.
- 559 4. Barbieri RR, Manta FSN, Moreira SJM, Sales AM, Nery JAC, Nascimento LPR, et al.
- Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: A follow-
- up study. PLoS Negl Trop Dis. 2019;13(3):e0007147.
- 562 5. Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment
- of leprosy. Med Mal Infect. 2015;45(9):383–93.
- 564 6. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev.
- 565 2015;28(1):80–94.
- 566 7. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive
- gene decay in the leprosy bacillus. Nature; 409(6823):1007–11.
- 568 8. Goulart IMB, Goulart LR. Leprosy: Diagnostic and control challenges for a worldwide
- disease. Arch Dermatol Res. 2008;300(6):269–90.
- 570 9. Tatipally S, Srikantam A, Kasetty S. Polymerase Chain Reaction (PCR) as a Potential
- Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review. Trop
- 572 Med Infect Dis. 2018;3(4):107.

- 573 10. Kralik P, Ricchi M. A basic guide to real time PCR in microbial diagnostics: Definitions.
- parameters, and everything. Front Microbiol. 2017;8(FEB):1–9.
- 575 11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid
- Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med. 2010
- 577 Sep 9;363(11):1005–15.
- 578 12. Scott L, David A, Govender L, Furrer J, Rakgokong M, Waja Z, et al. Performance of
- the Roche Cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis
- in a High HIV Burden Setting. J Mol Diagnostics. 2020;22(10):1225-1237.
- 581 13. Silva Feliciano C, José Bazzo Menon L, Maria Pala Anselmo L, Dippenaar A, Mark
- Warren R, Araújo Silva Jr W, et al. Xpert MTB/RIF performance to diagnose
- tuberculosis and rifampicin resistance in a reference centre in southern Brazil. 2019
- 584 Aug 5;5(3):00043-2019.
- 585 14. Fonseca B de P. Albuquerque PC, Zicker F. Neglected tropical diseases in Brazil: lack
- of correlation between disease burden, research funding and output. Trop Med Int
- 587 Heal. 2020 ;25(11):1373-1384
- 588 15. Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools
- and approaches to end the transmission of Mycobacterium leprae. Lancet Infect Dis.
- 590 2017 Sep;17(9):e298–305.
- 591 16. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, et al.
- 592 Evaluation of gPCR-Based assays for leprosy diagnosis directly in clinical specimens.
- 593 J Clin Microbiol. 2011 Jul 1;5(10):1–8.
- 594 17. Nobre ML, Amorim FM, de Souza MCF, de Neves-Manta FS, Esquenazi D, Moraes
- MO, et al. Multibacillary leprosy and the elderly: A field for further research. Lepr Rev.

- 596 2017;88(4):510–9.
- 597 18. da Silva Martinez T, Nahas AA, Figueira MMR, Costa A V., Gonçalves MA, Goulart
- LR, et al. Oral lesion in leprosy: Borderline tuberculoid diagnosis based on detection
- of mycobacterium leprae DNA by gPCR. Acta Derm Venereol. 2011;91(6):704–7.
- 600 19. Gama RS, Gomides TAR, Gama CFM, Moreira SJM, de Neves Manta FS, de Oliveira
- LBP, et al. High frequency of M. leprae DNA detection in asymptomatic household
- 602 contacts. BMC Infect Dis. 2018;18(1):153.
- 603 20. Reis EM, Araujo S, Lobato J, Neves AF, Costa AV, Gonçalves MA, et al.
- Mycobacterium leprae DNA in peripheral blood may indicate a bacilli migration route
- and high-risk for leprosy onset. Clin Microbiol Infect. 2014;20(5):447–52.
- 606 21. Goulart IMB, Cardoso AM, Santos MS, Gonçalves MA, Pereira JE, Goulart LR.
- Detection of Mycobacterium leprae DNA in skin lesions of leprosy patients by PCR
- may be affected by amplicon size. Arch Dermatol Res. 2007;299(5–6):267–71.
- 609 22. Caleffi KR, Hirata RDC, Hirata MH, Caleffi ER, Sigueira VLD, Cardoso RF. Use of the
- polymerase chain reaction to detect Mycobacterium leprae in urine. Brazilian J Med
- 611 Biol Res. 2012;45(2):153-7.
- 612 23. Maltempe FG, Baldin VP, Lopes MA, Siqueira VLD, Scodro RBDL, Cardoso RF, et al.
- Critical analysis: Use of polymerase chain reaction to diagnose leprosy. Brazilian J
- 614 Pharm Sci. 2016;52(1):163–9.
- 615 24. Azevedo M de CS, Ramuno NM, Fachin LRV, Tassa M, Rosa PS, Belone A de FF, et
- al. qPCR detection of Mycobacterium leprae in biopsies and slit skin smear of different
- leprosy clinical forms. Brazilian J Infect Dis. 2017;21(1):71–8.
- 618 25. Arunagiri K, Sangeetha G, Sugashini PK, Balaraman S, Showkath Ali MK. Nasal PCR

- assay for the detection of Mycobacterium leprae pra gene to study subclinical infection
- in a community. Microb Pathog. 2017;104:336–9.
- 621 26. Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, Gillis TP.
- Enumeration of Mycobacterium leprae Using Real-Time PCR. Small PLC, editor.
- 623 PLoS Negl Trop Dis. 2008 Nov 4;2(11):e328.
- 624 27. Banerjee S, Sarkar K, Gupta S, Mahapatra PS, Gupta S, Guha S, et al. Multiplex PCR
- technique could be an alternative approach for early detection of leprosy among close
- contacts a pilot study from India. BMC Infect Dis. 2010;10:1–8.
- 627 28. Donoghe HD, Holton J, Spigelman M. PCR primers that can detect low levels of
- Mycobacterium leprae DNA. J Med Microbiol. 2001;50(2):177–82.
- 629 29. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, et al. Molecular
- Determination of Mycobacterium leprae Viability by Use of Real-Time PCR. J Clin
- 631 Microbiol. 2009;47(7):2124–30.
- 632 30. Manta FS de N. Leal-Calvo T. Moreira SJM, Margues BLC, Ribeiro-Alves M, Rosa
- 633 PS, et al. Ultra-sensitive detection of Mycobacterium leprae: DNA extraction and PCR
- assays. Poonawala H, editor. PLoS Negl Trop Dis. 2020;14(5):e0008325.
- 635 31. Ridley D, Jopling W. Classification of leprosy according to immunity. A five-group
- 636 system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73.
- 637 32. Girma S, Avanzi C, Bobosha K, Desta K, Idriss MH, Busso P, et al. Evaluation of
- Auramine O staining and conventional PCR for leprosy diagnosis: A comparative
- cross-sectional study from Ethiopia. PLoS Negl Trop Dis. 2018;12(9):1–14.
- 640 33. Kramme S, Bretzel G, Panning M, Kawuma J, Drosten C. Detection and quantification
- of Mycobacterium leprae in tissue samples by real-time PCR. Med Microbiol Immunol.

- 642 2004;193(4):189–93.
- 643 34. Patrocínio LG, Goulart IMB, Goulart LR, Patrocínio JA, Ferreira FR, Fleury RN.
- Detection of Mycobacterium leprae in nasal mucosa biopsies by the polymerase chain
- reaction. FEMS Immunol Med Microbiol. 2005;44(3):311–6.
- 646 35. Phetsuksiri B, Rudeeaneksin J, Supapkul P, Wachapong S, Mahotarn K, Brennan PJ.
- A simplified reverse transcriptase PCR for rapid detection of Mycobacterium leprae in
- skin specimens. FEMS Immunol Med Microbiol. 2006;48(3):319–28.
- 649 36. Da Cunha FMB, Werneck MCM, Scola RH, Werneck LC. Pure neural leprosy:
- Diagnostic value of the polymerase chain reaction. Muscle and Nerve.
- 651 2006;33(3):409–14.
- 652 37. Santos AR, De Miranda AB, Sarno EN, Suffys PN, Degrave WM. Use of PCR-
- 653 mediated amplification of Mycobacterium leprae DNA in different types of clinical
- samples for the diagnosis of leprosy. J Med Microbiol. 1993 Oct 1;39(4):298–304.
- 655 38. Scollard DM, Gillis TP, Williams DL. Polymerase chain reaction assay for the detection
- and identification of Mycobacterium leprae in patients in the United States. Am J Clin
- 657 Pathol. 1998 May;109(5):642–6.
- 658 39. Martinez AN, Britto CFPC, Nery JAC, Sampaio EP, Jardim MR, Sarno EN, et al.
- 659 Evaluation of real-time and conventional PCR targeting complex 85 genes for
- detection of Mycobacterium leprae DNA in skin biopsy samples from patients
- diagnosed with leprosy. J Clin Microbiol. 2006;44(9):3154–9.
- 662 40. Rudeeaneksin J, Srisungngam S, Sawanpanyalert P, Sittiwakin T, Likanonsakul S,
- Pasadorn S, et al. LightCyclerTM real-time PCR for rapid detection and quantitation of
- Mycobacterium leprae in skin specimens. FEMS Immunol Med Microbiol.

- 665 2008;54(2):263–70.
- 666 41. Martinez AN, Talhari C, Moraes MO, Talhari S. PCR-Based Techniques for Leprosy
- Diagnosis: From the Laboratory to the Clinic. Franco-Paredes C, editor. PLoS Negl
- 668 Trop Dis. 2014 Apr 10;8(4):e2655.
- 669 42. Tiwari V, Malhotra K, Khan K, Maurya PK, Singh AK, Thacker AK, et al. Evaluation of
- polymerase chain reaction in nerve biopsy specimens of patients with Hansen's
- disease. J Neurol Sci. 2017;380:187–90.
- 672 43. Carvalho RS, Foschiani IM, Renata M, Nogueira S, Marta SN. Early detection of M.
- leprae by gPCR in untreated patients and their contacts: results for nasal swab and
- palate mucosa scraping Early detection of M. leprae by gPCR in untreated patients
- and their contacts: results for nasal swab and palate mucosa sc. Eur J Clin Microbiol
- 676 Infect Dis. 2018 Oct;37(10):1863-1867.
- 677 44. Woods SA, Cole ST. A rapid method for the detection of potentially viable
- Mycobacterium leprae in human biopsies: a novel application of PCR. FEMS Microbiol
- 679 Lett. 1989 Dec;53(3):305–9.
- 680 45. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases.
- 681 Clin Microbiol Rev. 2010;23(3):550–76.
- 682 46. Turankar RP, Pandey S, Lavania M, Singh I, Nigam A, Darlong J, et al. Comparative
- evaluation of PCR amplification of RLEP, 16S rRNA, rpoT and Sod A gene targets for
- detection of M. leprae DNA from clinical and environmental samples. Int J
- 685 Mycobacteriology. 2015;4(1):54–9.
- 686 47. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, et al. A
- standardized framework for the validation and verification of clinical molecular genetic

- 688 tests. Eur J Hum Genet. 2010;18(12):1276–88.
- 689 48. National Association of Testing Authorities A (NATA). Guidelines for the validation and
- verification of chemical methods. 2013;(December 2006:1–6.
- 691 49. Markoulatos P, Siafakas N, Moncany M. Multiplex polymerase chain reaction: A
- 692 practical approach. J Clin Lab Anal. 2002;16(1):47–51.
- 693 50. Lorenz TC. Polymerase Chain Reaction: Basic Protocol Plus Troubleshooting and
- Optimization Strategies. J Vis Exp. 2012;63:3998.
- 695 51. Gillini L, Cooreman E, Wood T, Pemmaraju VR, Saunderson P. Global practices in
- regard to implementation of preventive measures for leprosy. Phillips RO, editor. PLoS
- 697 Negl Trop Dis. 2017;11(5):e0005399.
- 698 52. Richardus JH, Tiwari A, Barth-jaeggi T, Arif MA, Banstola NL, Baskota R, et al.
- 699 Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an
- international feasibility programme. 2020;(20):10–4.
- 701 53. Manta FSN, Barbieri RR, Moreira SJM, Santos PTS, Nery JAC, Duppre NC, et al.
- Quantitative PCR for leprosy diagnosis and monitoring in household contacts: A
- 703 follow-up study, 2011–2018. Sci Rep. 2019 Dec 1;9(1):1–8.
- 704 54. Bobosha K, Tjon Kon Fat EM, van den Eeden SJF, Bekele Y, van der Ploeg-van Schip
- JJ, de Dood CJ, et al. Field-Evaluation of a New Lateral Flow Assay for Detection of
- 706 Cellular and Humoral Immunity against Mycobacterium leprae. PLoS Negl Trop Dis.
- 707 2014;8(5).
- 708 55. Van Hooij A, Fat EMTK, Van Den Eeden SJF, Wilson L, Da Silva MB, Salgado CG, et
- al. Field-friendly serological tests for determination of M. Leprae-specific antibodies.
- 710 Sci Rep . 2017;7(1):1–8.

711 56. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, 712 limitations, and future applications in acute-care settings. Lancet Infect Dis. 713 2004;4(6):337–48. 714 57. Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, Alam K, Vrolijk LB, Dlamini S, et al. 715 Fingerstick test quantifying humoral and cellular biomarkers indicative for M. leprae 716 infection. Clin Biochem. 2019;66:76-82. Van Hooij A, Van Den Eeden S, Richardus R, Tjon E, Fat K, Wilson L, et al. Application 717 58. 718 of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy 719 diagnosis in the field. EBioMedicine. 2019;47:301–8. 720 van Hooij A, Tió-Coma M, Verhard EM, Khatun M, Alam K, Tjon Kon Fat E, et al. 59. 721 Household Contacts of Leprosy Patients in Endemic Areas Display a Specific Innate 722 Immunity Profile. Front Immunol. 2020;11:1–12. 723 Ti O-Coma M, Kie»basa SM, Van Den Eeden SJF, Mei H, Roy JC, Wallinga J, et al. 60. 724 Blood RNA signature RISK4LEP predicts leprosy years before clinical onset-NC-ND 725 license EBioMedicine. 2021;68:103379.

726

727

Supplementary Table 1. Validation multiplex real-time qPCR assay study results.

Supplementary Table 2. Reproducibility and Repeatability results from synthetic DNA.

Supplementary Table 3. List of C_p cutoff value combinations with associated sensitivity and specificity scores.

Supplementary Table 4. Individual Ct values for targets included in the multiplex real-time qPCR assay (16S rRNA/RLEP/18SrRNA), sociodemographic, and laboratory variables for patients samples included in this study.


Author's contributions

- 744 F.S.N.M., T.J. Wrote the manuscript and contributed equally for this study;
- 745 F.S.N.M., T.J., R.C.P.R., N.Z., S.M., M.R.A. designed, performed, and analyzed
- 746 experiments;


742

743


- 747 F.S.N.M., M.O.M. supervised sample collection;
- 748 T.J., A.D.T.C. supervised production of kit prototypes;
- 749 M.A.K., M.O.M. secured funding;
- A.D.T.C., M.O.M. conceptualized the study and approved the final version of the manuscript
- and are co-senior authors of this study. Guarantors of the integrity of the data presented.




Figure




Figure




Figure




Figure



Figure



Figure



Figure